Contrast Agents

Monday, 24 May 1999
Hall C
14:00 – 16:00

Chairs: Jeff W.M. Bulte and Friedrich Cavagna

14:00 716. Dependence of Tumor Vascular Volume and Permeability on Radiation Treatment: Assessment by Contrast Agents of Various Molecular Weights. M-Y. Su, H. Yu and O. Nalcioglu, University of California, Irvine, CA, USA.
14:04 717. Dynamic Contrast-Enhanced MR Imaging of Abscess and VX2 Carcinoma in Rabbits: Comparison of 24 Gadolinium-DOTA-Dendrimer and Gadopentetate Dimeglumine, W.K. Moon, K.H. Chang and H.J. Weinmann, Seoul National University Hospital, Seoul, Korea and Schering AG, Berlin, Germany.
14:08 718. The Development of a Tumor Targeting Magnetic Resonance Contrast Agent Utilizing the High Affinity Folate Receptor, S.D. Konda, M. Aref and E.C. Wiener, University of Illinois at Urbana-Champaign, Urbana, IL, USA.
14:12 719. Kinetic Study of a New Contrast Agent for Brain MR Imaging on a Rat C6 Glioma Model, E. Fonchy, C. Rémy, A. François-Joubert, H. Lahrech, C. Rubin, R. Dupeyre, M. Décorps and S. Benderbous, INSERM, Grenoble, France and Laboratoire GUERBET, Aulnay-sous-bois, France.
14:16 720. Contrast Enhanced MRI of Implanted VX2 Tumors in Rabbit Muscle: Comparison of Gd-DTPA and NMS60, A.J. de Crespigny, D. Howard, H. Muller, H.E. D'Arceuil, S. Seri, Y. Hashiguchi, C. Fujimoto, A. Nakatani and M.E. Moseley, Stanford University, Stanford, CA, USA; Muller Associates, Palo Alto, CA, USA and Nihon Medi-Physics Co. Ltd., Chiba, Japan.
14:20 721. MR Lymphangiography: Use of Intradermal Injections of Combidex® Magnetite Nanoparticles to Visualize Lymphatic Ducts, J.M. Rogers, C.W. Jung and E.V. Groman, Advanced Magnetics, Inc., Cambridge, MA, USA.
14:24 722. Contrast-Enhanced MRI: Measurement of Angiogenesis in the Wound Healing Process, T.H. Helbich, T.P. Roberts, M.D. Rollins, D.M. Shames, K. Turetschek, H.W. Hopf, M. Mühler, T.K. Hunt and
R.C. Brasch, University of California, San Francisco, CA, USA.
14:28 723. In Vitro Characterization of MS-325 by Multinuclear Relaxometry, R.N. Muller, B. Radüchel, S. Laurent, J. Platzek, C. Piérart, P. Mareski and L. Vander Elst, University of Mons-Hainaut, Mons, Belgium and Schering AG, Berlin, Germany.
14:32 724. T1 and T2 NMRD Studies of Angiomark™ (MS-325), P. Caravan, J.W.M. Bulte, S.U. Dunham, J. Amedio and R.B. Lauffer, EPIX Medical Inc., Cambridge, MA, USA and National Institutes of Health, Bethesda, MD, USA.
14:36 725. Paramagnetic Liposomes as Thermosensitive Probes for MRI In Vitro Feasibility Studies, S.L. Fossheim, K.A. Il'yasov, U.N. Wiggen, A. Rogstad, J. Hennig, J. Klaveness and A. Bjørnerud, Nycomed Imaging AS, Oslo, Norway; University of Freiburg, Freiburg, Germany and University of Oslo, Oslo, Norway.
14:40 726. CBV Measurements with Steady-State Susceptibility Contrast: The Interest of Simultaneous and DR2 and DR2* Measurements, I. Troprès, E. Grillon, S. Grimault, C. Dolbec, H. Reutenauer and M. Décorps, Centre Hospitalier Universitaire, Grenoble, France.
14:44 727. Cerebral Blood Volume in Permanent Focal Cerebral Ischemia in Rat Studied with the Steady State Susceptility-Contrast Imaging, H. Seegers, I. Tropres, E. Grillon, H. Reutenauer, A. Jaillard, M. Décorps and M. Hommel, University Hospital, Grenoble, France.

Return to Poster Sessions

Return to ISMRM Program